Who is sponsoring NCT00912860?

NCT00912860 is sponsored by Biogen.

What condition does NCT00912860 study?

NCT00912860 studies Multiple Sclerosis.

What drugs are being tested in NCT00912860?

Interventions: Interferon beta-1a.

What is the status of NCT00912860?

NCT00912860 is currently COMPLETED.

Last reviewed 2009-06-05 · How we verify

A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis

NCT00912860 Phase 2 COMPLETED

To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.

Details

Lead sponsor	Biogen
Phase	Phase 2
Status	COMPLETED
Enrolment	155
Start date	2003-01
Completion	2005-01

Conditions

Multiple Sclerosis

Interventions

Interferon beta-1a

Primary outcomes

To evaluate the immunogenicity of a serum-free pre-formulated solution of AVONEX® — Study duration is 20 months